Ghent University Academic Bibliography

Advanced

CD248 and its cytoplasmic domain: a therapeutic target for Arthritis

Margarida Maia, Astrid de Vriese, Tom Janssens, Michael Moons, Kristel Van Landuyt, Jan Tavernier UGent, Rik J Lories and Eduard M Conway (2010) ARTHRITIS AND RHEUMATISM. 62(12). p.3595-3606
abstract
Objective. CD248 is a transmembrane glycoprotein expressed on the surface of activated perivascular and fibroblast-like cells. This study was undertaken to explore the function of CD248 and its cytoplasmic domain in arthritis. Methods. Synovial tissue biopsy samples from healthy controls, from patients with psoriatic arthritis (PsA), and from patients with rheumatoid arthritis (RA) were stained for CD248. Transgenic mice that were CD248-deficient (CD248-knockout [CD248(KO/KO)]) or mice with CD248 lacking the cytoplasmic domain (CD248(CyD/CyD)) were generated. Collagen antibody-induced arthritis (CAIA) was induced in these mice and in corresponding wild-type (WT) mice as controls. Clinical signs and histologic features of arthritis were evaluated. Cytokine levels were determined by enzyme-linked immunosorbent assay, and the number of infiltrating inflammatory cells was quantified by immuno-histochemistry. In vitro studies were performed with fibroblasts from CD248-transgenic mouse embryos to explain the observed effects on inflammation. Results. Immunostaining of synovium from patients with PsA and patients with RA and that from mice after the induction of CAIA revealed strong CD248 expression in perivascular and fibroblast-like stromal cells. CD248(KO/KO) and CD248(CyD/CyD) mice had less severe arthritis, with lower plasma levels of proinflammatory cytokines, as compared with WT controls. Moreover, the joints of these mice had less synovial hyperplasia, reduced accumulation of inflammatory cells, and less articular cartilage and bone damage. Tumor necrosis factor alpha-induced monocyte adhesion to CD248(CyD/CyD) fibroblasts was impaired. CD248(CyD/CyD) fibroblasts exhibited reduced expression of hypoxia-inducible factor 1 alpha, placental growth factor, vascular endothelial growth factor, and matrix metalloproteinase 9 activity in response to transforming growth factor beta. Conclusion. CD248 contributes to synovial hyperplasia and leukocyte accumulation in inflammatory arthritis, the effects of which are mediated partly via its cytoplasmic domain. CD248 is therefore a potential new target in the treatment of arthritis.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
TUMOR ENDOTHELIUM, STROMAL FIBROBLASTS, MONOCYTE ACTIVATION, ENDOTHELIAL-CELLS, PSORIATIC-ARTHRITIS, SYNOVIAL FIBROBLASTS, RHEUMATOID-ARTHRITIS, TUMOR ENDOTHELIUM, ENDOTHELIAL-CELLS, PLACENTA GROWTH-FACTOR, INNATE IMMUNITY, ENDOSIALIN TEM1, ENDOSIALIN TEM1, INNATE IMMUNITY
journal title
ARTHRITIS AND RHEUMATISM
Arthritis Rheum.
volume
62
issue
12
pages
3595 - 3606
Web of Science type
Article
Web of Science id
000285210200012
JCR category
RHEUMATOLOGY
JCR impact factor
8.435 (2010)
JCR rank
2/29 (2010)
JCR quartile
1 (2010)
ISSN
0004-3591
DOI
10.1002/art.27701
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1110112
handle
http://hdl.handle.net/1854/LU-1110112
date created
2011-01-25 16:26:15
date last changed
2016-12-19 15:46:20
@article{1110112,
  abstract     = {Objective. CD248 is a transmembrane glycoprotein expressed on the surface of activated perivascular and fibroblast-like cells. This study was undertaken to explore the function of CD248 and its cytoplasmic domain in arthritis.
Methods. Synovial tissue biopsy samples from healthy controls, from patients with psoriatic arthritis (PsA), and from patients with rheumatoid arthritis (RA) were stained for CD248. Transgenic mice that were CD248-deficient (CD248-knockout [CD248(KO/KO)]) or mice with CD248 lacking the cytoplasmic domain (CD248(CyD/CyD)) were generated. Collagen antibody-induced arthritis (CAIA) was induced in these mice and in corresponding wild-type (WT) mice as controls. Clinical signs and histologic features of arthritis were evaluated. Cytokine levels were determined by enzyme-linked immunosorbent assay, and the number of infiltrating inflammatory cells was quantified by immuno-histochemistry. In vitro studies were performed with fibroblasts from CD248-transgenic mouse embryos to explain the observed effects on inflammation.
Results. Immunostaining of synovium from patients with PsA and patients with RA and that from mice after the induction of CAIA revealed strong CD248 expression in perivascular and fibroblast-like stromal cells. CD248(KO/KO) and CD248(CyD/CyD) mice had less severe arthritis, with lower plasma levels of proinflammatory cytokines, as compared with WT controls. Moreover, the joints of these mice had less synovial hyperplasia, reduced accumulation of inflammatory cells, and less articular cartilage and bone damage. Tumor necrosis factor alpha-induced monocyte adhesion to CD248(CyD/CyD) fibroblasts was impaired. CD248(CyD/CyD) fibroblasts exhibited reduced expression of hypoxia-inducible factor 1 alpha, placental growth factor, vascular endothelial growth factor, and matrix metalloproteinase 9 activity in response to transforming growth factor beta.
Conclusion. CD248 contributes to synovial hyperplasia and leukocyte accumulation in inflammatory arthritis, the effects of which are mediated partly via its cytoplasmic domain. CD248 is therefore a potential new target in the treatment of arthritis.},
  author       = {Maia, Margarida and de Vriese, Astrid and Janssens, Tom and Moons, Michael and Van Landuyt, Kristel and Tavernier, Jan and Lories, Rik J and Conway, Eduard M},
  issn         = {0004-3591},
  journal      = {ARTHRITIS AND RHEUMATISM},
  keyword      = {TUMOR ENDOTHELIUM,STROMAL FIBROBLASTS,MONOCYTE ACTIVATION,ENDOTHELIAL-CELLS,PSORIATIC-ARTHRITIS,SYNOVIAL FIBROBLASTS,RHEUMATOID-ARTHRITIS,TUMOR ENDOTHELIUM,ENDOTHELIAL-CELLS,PLACENTA GROWTH-FACTOR,INNATE IMMUNITY,ENDOSIALIN TEM1,ENDOSIALIN TEM1,INNATE IMMUNITY},
  language     = {eng},
  number       = {12},
  pages        = {3595--3606},
  title        = {CD248 and its cytoplasmic domain: a therapeutic target for Arthritis},
  url          = {http://dx.doi.org/10.1002/art.27701},
  volume       = {62},
  year         = {2010},
}

Chicago
Maia, Margarida, Astrid de Vriese, Tom Janssens, Michael Moons, Kristel Van Landuyt, Jan Tavernier, Rik J Lories, and Eduard M Conway. 2010. “CD248 and Its Cytoplasmic Domain: a Therapeutic Target for Arthritis.” Arthritis and Rheumatism 62 (12): 3595–3606.
APA
Maia, M., de Vriese, A., Janssens, T., Moons, M., Van Landuyt, K., Tavernier, J., Lories, R. J., et al. (2010). CD248 and its cytoplasmic domain: a therapeutic target for Arthritis. ARTHRITIS AND RHEUMATISM, 62(12), 3595–3606.
Vancouver
1.
Maia M, de Vriese A, Janssens T, Moons M, Van Landuyt K, Tavernier J, et al. CD248 and its cytoplasmic domain: a therapeutic target for Arthritis. ARTHRITIS AND RHEUMATISM. 2010;62(12):3595–606.
MLA
Maia, Margarida, Astrid de Vriese, Tom Janssens, et al. “CD248 and Its Cytoplasmic Domain: a Therapeutic Target for Arthritis.” ARTHRITIS AND RHEUMATISM 62.12 (2010): 3595–3606. Print.